Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia

[1]  M. Labopin,et al.  Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 1997, Blood.

[2]  H. Rugo,et al.  A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia , 1997, Leukemia.

[3]  R. Gray,et al.  Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. , 1997, Blood.

[4]  M. Lee,et al.  Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia. , 1997, Leukemia & lymphoma.

[5]  B. Löwenberg,et al.  Application of myeloid growth factors in the treatment of acute myeloid leukemia , 1997, Leukemia.

[6]  M. Grever,et al.  A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.

[7]  J. Goldman,et al.  Intermediate‐dose busulphan before autografting for advanced‐phase chronic myeloid leukaemia , 1996, British journal of haematology.

[8]  R. Gray,et al.  Dose intensification in acute myloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's ATML9 study , 1996, British journal of haematology.

[9]  E. Bow,et al.  Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Reiffers,et al.  A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. , 1996, Leukemia.

[11]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[12]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[13]  J. Reiffers,et al.  Is there a place for blood stem-cell transplantation for the younger adult patient with acute myelogenous leukemia? BGMT Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Richard J. Jones.  Autologous bone marrow transplantation , 1993, Current opinion in oncology.

[15]  J. A. Liu Yin,et al.  ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENT , 1993, British journal of haematology.

[16]  A. Bartolucci,et al.  A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.

[18]  Janice Gabrilove,et al.  Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .

[19]  J. Gabrilove,et al.  Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. , 1991, Blood.

[20]  F. Mandelli,et al.  BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. , 1990, Blood.

[21]  P. Desai,et al.  Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. , 1990, Leukemia.

[22]  J. Matthews,et al.  Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. , 1990, Blood.

[23]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Bloomfield,et al.  The clinical significance of karyotype in acute myelogenous leukemia. , 1989, Cancer genetics and cytogenetics.

[25]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[26]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[27]  H. Preisler.  Failure of remission induction in acute myelocytic leukemia. , 1978, Medical and pediatric oncology.

[28]  C. Spurr,et al.  Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .